CARB-X Receives Additional $370m from U.S. Government and Wellcome

Enables continued investment in innovative projects to tackle the growing…


Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism

Alderley Park, Cheshire - Infex Therapeutics, one of the UK’s leading…


Infex scientists achieve breakthrough to overcome critical priority drug resistant infections

Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…


Infex agrees partnership with Colibri Scientific to provide services for RESP-X program

Alderley Park, Cheshire Infex Therapeutics has today announced a deal with…


Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains

Alderley Park, Cheshire –  One of the UK’s leading infectious disease biotech…


Tackling underlying respiratory conditions for this pandemic and next

During the COVID-19 pandemic, one of the many phrases that has become…


Infex partners with Alderley Analytical to provide PK and ADA analysis for RESP-X program

Alderley Park, Cheshire Infex Therapeutics has today announced a deal with…


Infex Therapeutics and LifeArc in Collaboration to Defeat Superbugs

Infex Therapeutics has combined forces with medical research charity, LifeArc,…


Introducing Infex Therapeutics

The organisation leading UK efforts to tackle the health crisis around our…